National Health Act 1953 - Amendment determination under subsections 85AB(1) and 85AC(1) - drugs on F1 and drugs in Part A of F2 (No. PB 47 of 2008)

Overview

The Amendment Determination — drugs on F1 and drugs in Part A of F2 (PB 47 of 2008) was enacted in 2008 under the authority of the National Health Act 1953, with amendments up to PB 57 of 2008. This legislative instrument was prepared by the Office of Legislative Drafting and Publishing, Attorney-General’s Department, and was designed to address the need for updating the list of specified drugs under the Commonwealth Register of Therapeutic Goods. This update ensures that the list remains current with new therapeutic options available to Australian patients. The instrument includes specific additions and amendments to the lists of drugs on F1 and in Part A of F2, reflecting the latest pharmacological advancements and therapeutic needs. The primary objective of this legislation is to maintain an accurate and comprehensive register of drugs that are available for use under the national health schemes, ensuring that healthcare providers have access to the most recent and effective treatments.

Scope and Application

The Amendment Determination — drugs on F1 and drugs in Part A of F2 (PB 47 of 2008) amends the listing of drugs under the National Health Act 1953. This legislative instrument applies to drugs listed on the First Schedule (F1) and drugs in Part A of the Second Schedule (F2) of the Act. The amendments specifically add "Lapatinib" to F1 and "Enalapril with hydrochlorothiazide" to both F1 and F2. The geographic and jurisdictional reach of this legislation is national, as it applies across Australia under the authority of the Commonwealth government. The legislation does not explicitly state any exclusions or exemptions, but it is subject to further amendment by subordinate instruments such as PB 57 of 2008, which came into effect on 30 April 2008 and made specific changes to the initial determination. This Amendment Determination is integral to the administration and regulation of pharmaceutical benefits under the National Health Act 1953.

Key Provisions

The Amendment Determination—drugs on F1 and drugs in Part A of F2 (PB 47 of 2008) as amended, made under the National Health Act 1953, primarily focuses on updating the list of drugs covered under certain legislative provisions. Specifically, Section 2 of the Amendment Determination introduces changes to Schedule 1, which adjusts the lists of drugs on F1 and F2. For instance, under Schedule 1, Item 2 adds "Lapatinib" alphabetically after "Darunavir" in the F1 list of drugs, and Item 3 introduces "Enalapril with hydrochlorothiazide" after "The listed drugs" in the F2 list of drugs. Additionally, Item 4 makes a corresponding amendment in Part A of F2 by inserting "Enalapril with hydrochlorothiazide" as the first entry and omitting a previous entry after "Octreotide." The obligations imposed by this legislation revolve around ensuring that the updated lists of drugs are correctly reflected in the relevant schedules. This includes administrative duties to amend records, ensure compliance with new drug classifications, and update any related documentation or communications. These changes likely aim to ensure that the regulatory framework remains current with medical advancements and the evolving landscape of pharmaceutical products. In terms of penalties and consequences, the Amendment Determination itself does not explicitly state penalties for non-compliance. However, under the broader National Health Act 1953, non-compliance with drug regulations can result in civil or criminal penalties. These may include fines, imprisonment, or both, depending on the severity of the breach. The specific penalties would be governed by the overarching legislation and the nature of the non-compliance, which might involve unauthorised use, supply, or distribution of the newly listed drugs. Ensuring adherence to these updated drug classifications is crucial to avoid legal repercussions and maintain the integrity of the national health regulatory framework.